290 related articles for article (PubMed ID: 30045663)
41. Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma.
Tan HW; Leung CO; Chan KK; Ho DW; Leung MS; Wong CM; Ng IO; Lo RC
Int J Cancer; 2019 Oct; 145(7):1860-1873. PubMed ID: 30834518
[TBL] [Abstract][Full Text] [Related]
42. CXCL11 promotes self-renewal and tumorigenicity of α2δ1
Zhang Y; Zhao W; Li S; Lv M; Yang X; Li M; Zhang Z
Cancer Lett; 2019 May; 449():163-171. PubMed ID: 30771435
[TBL] [Abstract][Full Text] [Related]
43. RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2.
Wang X; Wang J; Tsui YM; Shi C; Wang Y; Zhang X; Yan Q; Chen M; Jiang C; Yuan YF; Wong CM; Liu M; Feng ZY; Chen H; Ng IOL; Jiang L; Guan XY
Nat Commun; 2021 Mar; 12(1):1518. PubMed ID: 33750796
[TBL] [Abstract][Full Text] [Related]
44. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
[TBL] [Abstract][Full Text] [Related]
45. HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
Bi L; Ren Y; Feng M; Meng P; Wang Q; Chen W; Jiao Q; Wang Y; Du L; Zhou F; Jiang Y; Chen F; Wang C; Tang B; Wang Y
Cancer Res; 2021 Apr; 81(8):2015-2028. PubMed ID: 33602787
[TBL] [Abstract][Full Text] [Related]
46. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
[TBL] [Abstract][Full Text] [Related]
47. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
48. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
49. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
[TBL] [Abstract][Full Text] [Related]
50. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
51. Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3.
Wu CX; Xu A; Zhang CC; Olson P; Chen L; Lee TK; Cheung TT; Lo CM; Wang XQ
Mol Cancer Ther; 2017 Aug; 16(8):1531-1543. PubMed ID: 28522590
[TBL] [Abstract][Full Text] [Related]
52. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway.
Li B; Liu D; Yang P; Li HY; Wang D
Gene; 2019 Jul; 707():78-85. PubMed ID: 31075412
[TBL] [Abstract][Full Text] [Related]
53. Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling.
Gu Y; Wang Y; He L; Zhang J; Zhu X; Liu N; Wang J; Lu T; He L; Tian Y; Fan Z
Mol Cancer; 2021 Oct; 20(1):132. PubMed ID: 34649567
[TBL] [Abstract][Full Text] [Related]
54. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
55. CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma.
Ding H; Wang Y; Zhang H
J Pharmacol Sci; 2020 Jul; 143(3):219-225. PubMed ID: 32418739
[TBL] [Abstract][Full Text] [Related]
56. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
57. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
58. Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of β-catenin signaling.
Lei ZJ; Wang J; Xiao HL; Guo Y; Wang T; Li Q; Liu L; Luo X; Fan LL; Lin L; Mao CY; Wang SN; Wei YL; Lan CH; Jiang J; Yang XJ; Liu PD; Chen DF; Wang B
Oncogene; 2015 Jun; 34(24):3188-98. PubMed ID: 25893304
[TBL] [Abstract][Full Text] [Related]
59. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
60. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
